JP2019529433A - リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法 - Google Patents

リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法 Download PDF

Info

Publication number
JP2019529433A
JP2019529433A JP2019515291A JP2019515291A JP2019529433A JP 2019529433 A JP2019529433 A JP 2019529433A JP 2019515291 A JP2019515291 A JP 2019515291A JP 2019515291 A JP2019515291 A JP 2019515291A JP 2019529433 A JP2019529433 A JP 2019529433A
Authority
JP
Japan
Prior art keywords
lilotomab
rirotomabu
administered
satetraxetane
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019515291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529433A5 (enExample
Inventor
ダフレ ヨステイン
ダフレ ヨステイン
チューナー スィーモン
チューナー スィーモン
Original Assignee
ノルディック ナノベクター アルメン アクスイェ セルスカプ
ノルディック ナノベクター アルメン アクスイェ セルスカプ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノルディック ナノベクター アルメン アクスイェ セルスカプ, ノルディック ナノベクター アルメン アクスイェ セルスカプ filed Critical ノルディック ナノベクター アルメン アクスイェ セルスカプ
Publication of JP2019529433A publication Critical patent/JP2019529433A/ja
Publication of JP2019529433A5 publication Critical patent/JP2019529433A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2019515291A 2016-09-16 2017-09-15 リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法 Pending JP2019529433A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP16189191 2016-09-16
EP16189191.6 2016-09-16
EP17164164 2017-03-31
EP17164164.0 2017-03-31
EP17170641.9 2017-05-11
EP17170641 2017-05-11
EP17175768 2017-06-13
EP17175768.5 2017-06-13
PCT/EP2017/073336 WO2018050851A1 (en) 2016-09-16 2017-09-15 Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan

Publications (2)

Publication Number Publication Date
JP2019529433A true JP2019529433A (ja) 2019-10-17
JP2019529433A5 JP2019529433A5 (enExample) 2020-10-22

Family

ID=59895313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515291A Pending JP2019529433A (ja) 2016-09-16 2017-09-15 リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法

Country Status (14)

Country Link
US (2) US20190192703A1 (enExample)
EP (1) EP3512881A1 (enExample)
JP (1) JP2019529433A (enExample)
KR (1) KR20190054113A (enExample)
CN (1) CN109790219A (enExample)
AU (1) AU2017327772A1 (enExample)
BR (1) BR112019004838A2 (enExample)
CA (1) CA3035268A1 (enExample)
IL (1) IL265387A (enExample)
MX (1) MX2019003029A (enExample)
PH (1) PH12019550033A1 (enExample)
RU (1) RU2019110955A (enExample)
SG (2) SG11201901672RA (enExample)
WO (1) WO2018050851A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529436A (ja) * 2017-08-04 2020-10-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ［１，２，４］トリアゾロ［４，３−ａ］ピリジニル置換のインドール化合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
KR20240083769A (ko) 2022-12-05 2024-06-12 김원석 휴대할 수 있는 해수 정화 유닛용 물통

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518086A (ja) * 2010-01-29 2013-05-20 ノルディック ナノベクター エーエス 放射免疫コンジュゲートおよびその使用
JP2015501654A (ja) * 2011-12-13 2015-01-19 ノルディック ナノベクター アーエス 治療用キメラ型抗ｃｄ３７抗体ｈｈ１

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010462A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
EP3262166A4 (en) * 2015-02-24 2018-08-15 The Regents of The University of California Binding-triggered transcriptional switches and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518086A (ja) * 2010-01-29 2013-05-20 ノルディック ナノベクター エーエス 放射免疫コンジュゲートおよびその使用
JP2015501654A (ja) * 2011-12-13 2015-01-19 ノルディック ナノベクター アーエス 治療用キメラ型抗ｃｄ３７抗体ｈｈ１

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHAN BLAKKISRUD: "RED MARROW-ABSORBED DOSE FOR NON-HODGKIN LYMPHOMA PATIENTS TREATED WITH 177LU-LILOTOMAB 以下備考", THE JOURNAL OF NUCLEAR MEDICINE, vol. VOL:58, NR:1,, JPN5019008467, September 2016 (2016-09-01), US, pages 55 - 61, ISSN: 0004958764 *
JOHAN BLAKKISRUD: "TUMOR-ABSORBED DOSE FOR NON-HODGKIN LYMPHOMA PATIENTS TREATED WITH THE ANTI-CD37 以下備考", THE JOURNAL OF NUCLEAR MEDICINE, vol. VOL:58, NR:1,, JPN5019008468, 4 August 2016 (2016-08-04), US, pages 48 - 54, ISSN: 0004958765 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529436A (ja) * 2017-08-04 2020-10-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ［１，２，４］トリアゾロ［４，３−ａ］ピリジニル置換のインドール化合物
JP7266576B2 (ja) 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物

Also Published As

Publication number Publication date
MX2019003029A (es) 2019-09-13
KR20190054113A (ko) 2019-05-21
RU2019110955A3 (enExample) 2020-11-26
EP3512881A1 (en) 2019-07-24
RU2019110955A (ru) 2020-10-20
US20220160907A1 (en) 2022-05-26
PH12019550033A1 (en) 2019-07-29
CN109790219A (zh) 2019-05-21
US20190192703A1 (en) 2019-06-27
WO2018050851A1 (en) 2018-03-22
BR112019004838A2 (pt) 2019-06-04
CA3035268A1 (en) 2018-03-22
AU2017327772A1 (en) 2019-03-21
SG10202102588QA (en) 2021-04-29
IL265387A (en) 2019-05-30
SG11201901672RA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
Seidl Radioimmunotherapy with α-particle-emitting radionuclides
Weiden et al. Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results
Alam et al. A review of 177Lutetium-PSMA and 225Actinium-PSMA as emerging theranostic agents in prostate cancer
JP5468597B2 (ja) 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット
CN105451781B (zh) 用于上调抗原表达的方法
RU2770073C2 (ru) Радиотерапевтические частицы и суспензии
Bodet-Milin et al. Radioimmunotherapy for treatment of acute leukemia
EP2497501B1 (en) Radionuclides for medical use
US20220160907A1 (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
Buchmann et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities
Sartor et al. Targeted use of alpha particles: current status in cancer therapeutics
US20210236664A1 (en) Alpha particle formulations for treatment of solid tumors
Farzipour et al. Evaluation of the Effect of Chelating Arms and Carrier Agents on the Radiotoxicity of TAT Agents
Koenecke et al. Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia
WO2025022285A2 (en) Psma-targeting radioligand treatment regimen
Bailly et al. Radioimmunotherapy of lymphomas
Saha Therapeutic uses of radiopharmaceuticals in nuclear medicine
Lepareur Transarterial radionuclide therapy with 188Re-labelled lipiodol
Jadvar Sequential and Combination Therapies of 223RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy
Hlongwa et al. The advent of Astatine-211 in targeted radionuclide therapy in prostate cancer: will it come to true fruition?
Sowa Dumond et al. Concepts and issues for therapeutic radiopharmaceuticals
Rathmann Development of a Versatile Platform for Combination Targeted Radionuclide and Immune Cell Recruitment Therapies Using Bio-Orthogonal Chemistry
Bailly et al. of Lymphomas
Kauffman Preclinical Development of Alpha-Particle Therapeutics
Illidge et al. Radioimmunotherapy of Hematological Malignancies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110